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A possible role for the intracellular Ca2+-homeostasis in the 
development of cisplatin-resistance in squamous lung carcinoma 
cells
Huber, Rudolf M.; Oelmez, Hamza; Bergner, Albrecht 
Pneumology, Medizinische Klinik-Innenstadt, LMU, Munich, Germany
Background: In the treatment of lung cancer, the effectiveness of 
chemotherapy is hampered by the development of therapy-resistance. 
Calcium is a universal second messenger involved in the regulation of 
virtually all cell function including apoptosis and cell death. Aim of 
this study was to investigate if the intracellular Ca2+-homeostasis of 
lung cancer cells may inﬂuence the development of therapy-resistance 
to cisplatin.
Methods: ATP served as an agonist to stimulate squamous lung 
carcinoma cells (EPLC) and the increase in cytoplasmatic calcium 
([Ca2+]c) was quantiﬁed using ﬂuorescence microscopy. The Ca2+-
indicator rhod-2 was used to quantify the mitochondrial Ca2+-con-
tent. EPLC cells were exposed to 0.5, 1 and 2 µg/ml cisplatin for 3h 
simulating the in vivo pharmacokinetics. The Ca2+-chelator BAPTA 
was used to study the effects of a reduced [Ca2+]c on the effectiveness 
of cisplatin.
Results: Using appropriate inhibitors, we could show that the ATP-
induced Ca2+-increase was due to Ca2+-release from the sarcoplasmic 
reticulum involving IP3- and Ryanodine-receptors with Ca2+-inﬂux 
from the extracellular space playing a minor role. Exposure to cisplatin 
led to a time dependent increase in the mitochondrial Ca2+-content. 
After 4 “cycles” of cisplatin the EPLC cells showed an increased 
survival compared to naïve EPLC cells. This therapy-resistance could 
be mimicked buffering [Ca2+]c with BAPTA. In the resistant clone, 
the ATP-induced Ca2+-increase was found to be signiﬁcantly reduced 
compared to naïve cells.
Conclusions: The intracellular Ca2+-homeostasis of lung carcinoma 
cells plays a signiﬁcant role in the development of cisplatin-resistance 
and may therefore constitute a novel approach to overcome therapy-
resistance.
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Expression of vascular endothelial growth factors (VEGFs) A, C, D 
and receptors (VEGFRs) 1, 2 and 3, in both tumor cells and tumor 
stroma of non-small cell lung cancer (NSCLC): correlation with 
lymph node metastasis
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Purpose: Nodal status is an important prognostic factor and a major 
determinant for the staging and clinical management of NSCLC. The 
vascular endothelial growth factors (VEGFs) and the vascular endothe-
lial growth factor receptors (VEGFRs) are important molecular markers 
in angiogenesis and lymphangiogenesis. In this study, we aimed to 
extensively investigate the correlations between lymph node metastasis 
and the VEGFs and VEGFRs in tumor cells as well as in the tumor 
stroma.
Methods: Tumor tissue samples from 335 resected patients with stage 
I to IIIA were obtained and tissue microarrays were constructed from 
duplicate cores of tumor cells and surrounding stromal tissue from each 
resected specimen. Immunohistochemistry was used to evaluate the 
expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2 and 
VEGFR-3.
Results: There were 232 lymph node metastasis negative- and 103 
lymph node metastasis positive patients (76 N1, 27 N2). In univariate 
analyses (Chi-square test), high tumor cell expression of VEGF-A (P = 
.011) and VEGFR-3 (P < .001) correlated with lymph node metastasis. 
In tumor stroma, however, low expression of VEGF-A (P = .037) and 
VEGFR-3 (P = .033), correlated with lymph node metastasis. There 
were no signiﬁcant correlations between tumor cell or stromal expres-
sion of VEGF-C, VEGF-D, VEGFR-1 or VEGFR-2 and lymph node 
metastasis. Though, high tumor cell expression of VEGFR-1 (P = .065) 
and low stromal expression of VEGFR-1 (P = .075) tended towards 
correlation with lymph node metastasis. In multivariate analyses 
(Binary logistic regression), including clinicopathogical variables and 
angiogenic markers, high tumor cell expression of VEGF-A (P = .032, 
HR 1.8, 95% CI 1.1-3.1), low stromal expression of VEGF-A (P = .025, 
HR 3.1, 95% CI 1.2 - 8.3) and poor differentiation (P < .001, HR 3.4, 
95% CI 2.0-5.9) correlated with lymph node positive patients. High tu-
mor cell expression of VEGFR-3 (P < .001, HR 6.1, 95% CI 2.1-17.6) 
and vascular inﬁltration (P = .011, HR 3.9, 95% CI 1.4-11.2) correlated 
with N2 positivity.
Conclusion: In tumor cells, there are strong correlations between high 
VEGFR-3 expression and N2-status and high VEGF-A expression and 
lymph node metastasis. While in stroma, low VEGF-A expression is 
associated with lymph node metastasis.
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Background: Lung cancer is the most common incident form of malig-
nancy and also the leading cause of cancer death worldwide. Although 
many genomic alterations have been observed in lung cancer, their 
clinicopathological signiﬁcance has not been thoroughly investigated. 
This study screened the genomic aberrations across the whole genome 
of non-small cell lung cancer cells with high-resolution and investi-
gated their clinicopathological implications.
Method: One Mb-resolution array comparative genomic hybridization 
(array-CGH) was applied to 31 squamous cell carcinomas and 24 ad-
enocarcinomas of lung. Copy number alteration was detected by using 
web based array-CGH analysis software named arrayCyGHt (http://ge-
nomics.catholic.ac.kr/arrayCGH/). The recurrent genomic alterations 
were analyzed for the association with the clinicopathological features 
of lung cancer. Signiﬁcance of the association between MAR and 
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clinicopathological parameters was tested by Chi-square test, two-sided 
Fisher’s exact test, and Cox regression using SPSS version 12.0 and 
STATA version 7.0 software. 
Result: Overall, 36 amplicons, 3 homozygous deletions, and 17 
minimally altered regions (MAR) common to many lung cancers were 
identiﬁed. Among them, genomic changes on 13q21, 1p32, Xq and Yp 
were found to be signiﬁcantly associated with clinical features, such 
as age, stage, and disease recurrence. Kaplan-Meier survival analysis 
revealed that genomic changes on 10p, 16q, 9p, 13q, 6p21 and 19q13 
were associated with poor survival. Multivariate analysis showed that 
alterations on 6p21, 7p, 9q, and 9p were remained as independent 
predictors for poor outcome. In addition, signiﬁcant correlations were 
observed for 3 pairs of MARs (19q13 and 6p21, 19p13 and 19q13, and 
8p12 and 8q11), which indicated their possible collaborative roles. We 
examined the expression level of ECT2, one of the genes located in the 
most recurrently gained region on 3q26 by real-time qPCR. Expression 
of ECT2 was generally appeared to be up-regulated in NSCLCs. 
Conclusion: These results show that the novel genomic alterations 
identiﬁed in this study along with their clinicopathological implications 
would be useful to elucidate molecular mechanisms of lung cancer and 
to identify reliable biomarkers for clinical application.
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Background: Lung cancer is a leading cause of cancer death world-
wide. Non-small cell lung cancer (NSCLC) accounts for ~85% of lung 
cancers, with squamous cell carcinoma (SqCC) and adenocarcinoma 
(AC) comprising the two main subtypes. SqCC typically develops in 
the central airways, and AC characteristically originates in the periph-
eral lung. Although these subtypes can be distinguished readily at the 
histological level, knowledge of the genetic mechanisms underlying 
their differences will lead to the development of novel disease speciﬁc 
therapeutic strategies. Previous studies suggest that distinct patterns 
of genomic alteration exist for AC and SqCC. However, the speciﬁc 
genes responsible for the different tumor phenotypes remain largely 
unknown. Initial gene expression proﬁling studies have yielded some 
insight into the tumor subtypes and are able to segregate tumors into 
histologic groupings based on multi-gene models. Since not all gene 
expression changes are causal to disease development, it is challenging 
to distinguish critical events from reactive changes through global gene 
expression proﬁles alone. Thus, an integrative approach is necessary to 
fully understand the causal genetic events and downstream effects on 
disease phenotype. 
Objective: To comprehensively identify the underlying molecular 
differences between SqCC and AC using an integrative genome and 
transcriptome analysis. The discovery of genes differentially altered in 
each phenotype may clarify mechanisms of tumor differentiation and 
identify novel molecular targets for early diagnosis and therapy 
Methods: A whole genome tiling path CGH array was used to gener-
ate copy number proﬁles of 103 AC and 58 SqCC tumors. This array 
allows the detection of small segmental alterations such as micro-am-
pliﬁcations and focal deletion which may have been undetected by con-
ventional cytogenetic methods. Array data was visualized using SeeGH 
software and subjected to a smoothing computational algorithm to 
determine chromosomal areas of gain and loss. The resulting frequen-
cies of alteration for each locus were compared between AC and SqCC 
using Fisher’s Exact Test and regions with difference of p<0.001 were 
considered statistically signiﬁcant. This genomic data was then inte-
grated with genome wide expression data to identify genes deregulated 
as a result of copy number alterations speciﬁc to each NSCLC subtype. 
Results: Subtype speciﬁc copy number changes were identiﬁed. 
Regions of alteration disparity were mapped to chromosomes arms 2p, 
3q, 4p, 4q, 8p, 12p, 19p, 19q, 20p and 22q. Analysis of expression data 
for the genes in these regions identiﬁed 183 unique genes differentially 
expressed between the subtypes as a result of copy number changes. 
Clustering and principle component analysis conﬁrmed that these 
gene signatures were able to accurately delineate the disease subtypes. 
Grouping of these genes by biological function showed that many im-
portant pathways are differentially altered in AC and SqCC in disease 
speciﬁc ways. 
Conclusions: Whole genome array CGH comparison between AC 
and SqCC tumor genomes identiﬁed tumor subtype-speciﬁc genetic 
alterations. Integration of gene expression data delineated genes and 
pathways that could be important in phenotype differentiation. Charac-
terization of these genes is now underway with the aim of deﬁning new 
molecular targets for early diagnosis and treatment.
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Background: Prevention of primary tumour development remains to 
be the foundation for lung cancer control. Chemoprevention is deﬁned 
as a pharmacologic intervention to suppress or reverse the carcinogenic 
process, and effective chemoprevention agents for lung cancer are 
needed. Due to effective public health campaigns for tobacco control, 
many lung cancers now arise in former smokers. We hypothesise that 
genomic changes common to current and former smokers represent 
authentic, permanent molecular changes altered by tobacco-smoke and 
may therefore represent crucial aberrations that lead to tobacco-smoke 
related lung carcinogenesis. Hence, the identiﬁcation of these causal 
smoking-related lung cancer genes represent drug-able targets for the 
development of novel or natural chemoprevention agents for the pre-
vention of lung cancer in former smokers.
Methods: We analysed a total of 84 fresh tumour tissues from resected 
primary non-small cell lung carcinomas (NSCLCs): 46 current smok-
ers (still smoking or quit less than one year prior to surgical resec-
tion), 26 former smokers (quit more than ten years prior to surgical 
resection), and 12 never smokers (smoked less than 100 cigarettes 
in lifetime). All smokers had at least 20 pack-years smoking history. 
Patients were matched on age (±10 years) and tobacco-smoke exposure 
(±10 pack-years). There was no signiﬁcant difference in sex, histol-
ogy, age or tobacco-smoke exposure between smoking groups. High 
molecular weight tumour DNA was digested, ﬂuorescently labelled and 
